[Ketotifen, a new prophylactic agent in asthma (author's transl)].
12 patients with bronchial asthma received treatment with Ketotifen for three months. 8 patients then continued this medication for at least 9 months. During this period it was possible to reduce the amount of theophylline and bronchodilator amines as well as the maintenance dose of corticosteroids. Afterwards 6 patients showed clinical deterioration while on placebo; this was considered further evidence of the anti-asthmatic effect of Ketotifen. Ketotifen seems to be acceptable as a prophylactic agent in asthma.
D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D000324:Adrenocorticotropic Hormone / Q000627:therapeutic use; D001249:Asthma / Q000517:prevention & control*; D002648:Child; D005260:Female; D006801:Humans; D007665:Ketotifen; D008297:Male; D008875:Middle Aged; D010880:Piperidines / Q000627:therapeutic use*; D010919:Placebos; D013806:Theophylline / Q000627:therapeutic use; D013876:Thiophenes / Q000627:therapeutic use*
D000305:Adrenal Cortex Hormones; D010880:Piperidines; D010919:Placebos; D013876:Thiophenes; D000324:Adrenocorticotropic Hormone; D013806:Theophylline; D007665:Ketotifen
Ketotifen, ein neues Asthmaprophylaktikum.